$19.43
2.91% today
Nasdaq, Apr 02, 09:18 pm CET
ISIN
US45249V1070
Symbol
ELVN
Sector
Industry

Imara Inc Stock price

$18.88
-0.74 3.77% 1M
-7.12 27.38% 6M
-3.62 16.09% YTD
-0.02 0.11% 1Y
+11.40 152.41% 3Y
-44.12 70.03% 5Y
-41.12 68.53% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.80 4.07%
ISIN
US45249V1070
Symbol
ELVN
Sector
Industry

Key metrics

Market capitalization $925.20m
Enterprise Value $611.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.98
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-104.55m
Free Cash Flow (TTM) Free Cash Flow $-73.24m
Cash position $313.49m
EPS (TTM) EPS $-1.90
P/E forward negative
P/S forward 129,525.41
EV/Sales forward 85,637.69
Short interest 35.17%
Show more

Is Imara Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Imara Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Imara Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Imara Inc forecast:

Buy
100%

Financial data from Imara Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.32 0.32
7% 7%
-
-0.32 -0.32
7% 7%
-
- Selling and Administrative Expenses 23 23
26% 26%
-
- Research and Development Expense 80 80
25% 25%
-
-104 -104
25% 25%
-
- Depreciation and Amortization 0.32 0.32
7% 7%
-
EBIT (Operating Income) EBIT -105 -105
25% 25%
-
Net Profit -89 -89
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about Imara Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Imara Inc Stock News

Neutral
PRNewsWire
20 days ago
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo. , Mar. 13, 2025 /PRNewswire/ -- Enliven The...
Neutral
PRNewsWire
about one month ago
BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m.

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Samuel Kintz
Employees 62
Founded 2019
Website www.enliventherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today